In this regard, Onen et al. evaluated whether the association between the mTOR-specific inhibitor RAD001 (Everolimus) and platinum-based chemotherapeutics (cisplatin and oxaliplatin) could enhance the antitumor effects of the latter against a mesothelioma cell line (MSTO-211H) [19]. Here, MTOR is linked to mesothelioma.